Literature DB >> 33594843

Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.

Manal A Ibrahim1, Hanan H Ramadan2, Rasha N Mohammed1.   

Abstract

Coronavirus COVID-19 pandemic invades the world. Public health evaluates the incidence of infections and death, which should be reduced and need desperately quarantines for infected individuals. This article review refers to the roles of Ginkgo Biloba to reduce the risk of infection in the respiratory tract, the details on the epidemiology of corona COVID-19 and influenza, and it highlights how the Ginko Biloba could have been used as a novel treatment.Ginkgo Biloba can reduce the risk of infection by several mechanisms; these mechanisms involve Ginkgo Biloba contains quercetin and other constituents, which have anti-inflammatory and immune modulator effects by reducing pro-inflammatory cytokines concentrations. Cytokines cause inflammation which have been induced the injuries in lung lining.Some observational studies confirmed that Ginkgo Biloba reduced the risk of asthma, sepsis and another respiratory disease as well as it reduced the risk of cigarette smoking on respiratory symptoms. While other evidences suggested the characters of Ginkgo Biloba as an antivirus agent through several mechanisms. Ginkgolic acid (GA) can inhibit the fusion and synthesis of viral proteins, thus, it inhibit the Herpes Simplex Virus type1 (HSV-1), genome replication in Human Cytomegalovirus (HCMV) and the infections of the Zika Virus (ZIKV). Also, it inhibits the wide spectrum of fusion by inhibiting the three types of proteins that have been induced fusion as (Influenza A Virus [IAV], Epstein Barr Virus [EBV], HIV and Ebola Virus [EBOV]).The secondary mechanism of GA targeting inhibition of the DNA and protein synthesis in virus, greatly have been related to its strong effects, even afterward the beginning of the infection, therefore, it potentially treats the acute viral contaminations like (Measles and Coronavirus COVID-19). Additionally, it has been used topically as an effective agent on vigorous lesions including (varicella-zoster virus [VZV], HSV-1 and HSV-2). Ginkgo Biloba may be useful for treating the infected people with coronavirus COVID-19 through its beneficial effect. To assess those recommendations should be conducted with random control trials and extensive population studies.
© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; Ginkgo Biloba; Ginkgolic acids; Quercetin; coronavirus; respiratory tract infection

Mesh:

Substances:

Year:  2021        PMID: 33594843     DOI: 10.1515/jbcpp-2020-0310

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  7 in total

1.  Alleviation of Post-COVID-19 Cognitive Deficits by Treatment with EGb 761®: A Case Series.

Authors:  Udo A Zifko; Muhammad Yacob; Benedikt J Braun; Gunnar P H Dietz
Journal:  Am J Case Rep       Date:  2022-09-26

Review 2.  Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review.

Authors:  Joanna Nawrot; Justyna Gornowicz-Porowska; Jaromir Budzianowski; Gerard Nowak; Grzegorz Schroeder; Joanna Kurczewska
Journal:  Cells       Date:  2022-06-11       Impact factor: 7.666

Review 3.  Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?

Authors:  Theoharis C Theoharides
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.682

Review 4.  Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality.

Authors:  Sunitha Kodidela; Sandip Godse; Asit Kumar; Xuyen H Nguyen; Alina Cernasev; Lina Zhou; Ajay Kumar Singh; Hari K Bhat; Santosh Kumar
Journal:  Biology (Basel)       Date:  2022-01-23

5.  Flavonoids for Treating Viral Acute Respiratory Tract Infections: A Systematic Review and Meta-Analysis of 30 Randomized Controlled Trials.

Authors:  Jia Yao; Yuan Zhang; Xian-Zhe Wang; Jia Zhao; Zhao-Jun Yang; Yu-Ping Lin; Lu Sun; Qi-Yun Lu; Guan-Jie Fan
Journal:  Front Public Health       Date:  2022-02-16

Review 6.  Ginkgo biloba in the management of the COVID-19 severity.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Ajeet Kaushik; Małgorzata Kujawska; Gaber El-Saber Batiha
Journal:  Arch Pharm (Weinheim)       Date:  2022-06-07       Impact factor: 4.613

7.  Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Authors:  Yu-Chen Yan; Zhi-Heng Xu; Jian Wang; Wen-Bo Yu
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.